Sutro Biopharma Inc
NASDAQ:STRO

Watchlist Manager
Sutro Biopharma Inc Logo
Sutro Biopharma Inc
NASDAQ:STRO
Watchlist
Price: 3.58 USD -9.6%
Market Cap: 293.4m USD
Have any thoughts about
Sutro Biopharma Inc?
Write Note

Intrinsic Value

STRO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one STRO stock under the Base Case scenario is 3.87 USD. Compared to the current market price of 3.58 USD, Sutro Biopharma Inc is Undervalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

STRO Intrinsic Value
3.87 USD
Undervaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sutro Biopharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for STRO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about STRO?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Sutro Biopharma Inc

Provide an overview of the primary business activities
of Sutro Biopharma Inc.

What unique competitive advantages
does Sutro Biopharma Inc hold over its rivals?

What risks and challenges
does Sutro Biopharma Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sutro Biopharma Inc.

Provide P/S
for Sutro Biopharma Inc.

Provide P/E
for Sutro Biopharma Inc.

Provide P/OCF
for Sutro Biopharma Inc.

Provide P/FCFE
for Sutro Biopharma Inc.

Provide P/B
for Sutro Biopharma Inc.

Provide EV/S
for Sutro Biopharma Inc.

Provide EV/GP
for Sutro Biopharma Inc.

Provide EV/EBITDA
for Sutro Biopharma Inc.

Provide EV/EBIT
for Sutro Biopharma Inc.

Provide EV/OCF
for Sutro Biopharma Inc.

Provide EV/FCFF
for Sutro Biopharma Inc.

Provide EV/IC
for Sutro Biopharma Inc.

Show me price targets
for Sutro Biopharma Inc made by professional analysts.

What are the Revenue projections
for Sutro Biopharma Inc?

How accurate were the past Revenue estimates
for Sutro Biopharma Inc?

What are the Net Income projections
for Sutro Biopharma Inc?

How accurate were the past Net Income estimates
for Sutro Biopharma Inc?

What are the EPS projections
for Sutro Biopharma Inc?

How accurate were the past EPS estimates
for Sutro Biopharma Inc?

What are the EBIT projections
for Sutro Biopharma Inc?

How accurate were the past EBIT estimates
for Sutro Biopharma Inc?

Compare the revenue forecasts
for Sutro Biopharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sutro Biopharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sutro Biopharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sutro Biopharma Inc compared to its peers.

Compare the P/E ratios
of Sutro Biopharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Sutro Biopharma Inc with its peers.

Analyze the financial leverage
of Sutro Biopharma Inc compared to its main competitors.

Show all profitability ratios
for Sutro Biopharma Inc.

Provide ROE
for Sutro Biopharma Inc.

Provide ROA
for Sutro Biopharma Inc.

Provide ROIC
for Sutro Biopharma Inc.

Provide ROCE
for Sutro Biopharma Inc.

Provide Gross Margin
for Sutro Biopharma Inc.

Provide Operating Margin
for Sutro Biopharma Inc.

Provide Net Margin
for Sutro Biopharma Inc.

Provide FCF Margin
for Sutro Biopharma Inc.

Show all solvency ratios
for Sutro Biopharma Inc.

Provide D/E Ratio
for Sutro Biopharma Inc.

Provide D/A Ratio
for Sutro Biopharma Inc.

Provide Interest Coverage Ratio
for Sutro Biopharma Inc.

Provide Altman Z-Score Ratio
for Sutro Biopharma Inc.

Provide Quick Ratio
for Sutro Biopharma Inc.

Provide Current Ratio
for Sutro Biopharma Inc.

Provide Cash Ratio
for Sutro Biopharma Inc.

What is the historical Revenue growth
over the last 5 years for Sutro Biopharma Inc?

What is the historical Net Income growth
over the last 5 years for Sutro Biopharma Inc?

What is the current Free Cash Flow
of Sutro Biopharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Sutro Biopharma Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Sutro Biopharma Inc

Current Assets 443.5m
Cash & Short-Term Investments 426m
Receivables 7m
Other Current Assets 10.5m
Non-Current Assets 45.6m
PP&E 39.7m
Other Non-Current Assets 5.8m
Current Liabilities 130m
Accounts Payable 6.1m
Accrued Liabilities 49.9m
Other Current Liabilities 74m
Non-Current Liabilities 206.9m
Other Non-Current Liabilities 206.9m
Efficiency

Earnings Waterfall
Sutro Biopharma Inc

Revenue
169.4m USD
Operating Expenses
-275.5m USD
Operating Income
-106.1m USD
Other Expenses
-18.3m USD
Net Income
-124.4m USD

Free Cash Flow Analysis
Sutro Biopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

STRO Profitability Score
Profitability Due Diligence

Sutro Biopharma Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
Declining ROE
Declining ROIC
18/100
Profitability
Score

Sutro Biopharma Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

STRO Solvency Score
Solvency Due Diligence

Sutro Biopharma Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
42/100
Solvency
Score

Sutro Biopharma Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

STRO Price Targets Summary
Sutro Biopharma Inc

Wall Street analysts forecast STRO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STRO is 12.24 USD with a low forecast of 5.05 USD and a high forecast of 21 USD.

Lowest
Price Target
5.05 USD
41% Upside
Average
Price Target
12.24 USD
242% Upside
Highest
Price Target
21 USD
487% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for STRO?

Click here to dive deeper.

Dividends

Sutro Biopharma Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for STRO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Sutro Biopharma Inc Logo
Sutro Biopharma Inc

Country

United States of America

Industry

Biotechnology

Market Cap

324.2m USD

Dividend Yield

0%

Description

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.

Contact

CALIFORNIA
South San Francisco
111 Oyster Point Blvd.
+16503928412.0
www.sutrobio.com

IPO

2018-09-27

Employees

224

Officers

CEO & Director
Mr. William J. Newell J.D.
Chief Scientific Officer
Dr. Hans-Peter Gerber Ph.D.
Chief Medical Officer
Dr. Anne Elizabeth Borgman-Hagey M.D.
President & COO
Ms. Jane Chung R.Ph.
Founder
Dr. James R. Swartz DSc, Ph.D., Sc.D.
CFO & Secretary
Mr. Edward C. Albini M.B.A
Show More
Chief Technical Operations Officer
Dr. Venkatesh Srinivasan Ph.d.
General Counsel
Mr. David Pauling J.D., M.A.
Chief People & Communications Officer
Ms. Linda A. Fitzpatrick
Chief Business Development Officer
Dr. Barbara Leyman Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one STRO stock?

The intrinsic value of one STRO stock under the Base Case scenario is 3.87 USD.

Is STRO stock undervalued or overvalued?

Compared to the current market price of 3.58 USD, Sutro Biopharma Inc is Undervalued by 7%.

Back to Top